Clarity Pharmaceuticals secures major manufacturing deal with Theragenics for copper-64 isotope production. The agreement establishes a robust supply chain for its lead prostate cancer agent, 64Cu-SAR-bisPSMA, ahead of anticipated FDA approval. Theragenics' Atlanta facility features 14 cyclotrons capable of producing approximately 2,000 patient doses daily. The extended 48-hour shelf life of 64Cu-SAR-bisPSMA offers significant logistical advantages over standard isotopes. Phase III AMPLIFY trial exceeded recruitment targets within nine months, while recent clinical data demonstrates superior lesion detection compared to standard imaging, prompting management changes in 44 percent of patients. This manufacturing partnership positions Clarity for commercial-scale production across multiple oncology indications.
Post from MarketNews_en
Log in to interact with content.